FDA, EMA Lay Out Incretin Mimetic Safety Analysis In NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Editorial details the breadth of data that U.S. and European regulators examined in concluding that available data are “inconsistent” with assertions that a causal association exists between incretin-based diabetes drugs and pancreatic adverse events.
You may also be interested in...
FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.
COVID-19 Vaccines: Advisory Committee Picks Apart US FDA Guidance On Efficacy Endpoints
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
Cast Members In US FDA’s COVID-19 Vaccine Advisory Committee
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: